002390.SZ
信邦制药
SZSE · Healthcare · F 批发零售 · CN
CNY 3.00
−1.32%Year over year
Reported trailing growth
- Revenue
- -7.6%
- EBITDA
- —
- EBIT
- +6.5%
- EPS
- +53.3%
- Free cash flow
- +13.9%
- Operating cash flow
- +5.2%
Forward estimates
Based on analyst estimates
- Revenue
- -58.8%
- EBITDA
- -44.6%
- EPS
- -2.7%
Three-year CAGR
- Revenue
- -4.0%
- EBITDA
- -8.1%
- EBIT
- -9.1%
- Net income
- -18.8%
- EPS
- -19.2%
- Free cash flow
- +14.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026